CAJ | 학술논문

目的：探讨重组人干扰素α-1b雾化治疗儿童呼吸道病毒感染性疾病的临床疗效及安全性。方法采用随机、对照的临床试验设计，将375例儿童呼吸道病毒感染性疾病患儿分为治疗组250例和对照组125例，除常规治疗外，治疗组加用重组人干扰素α-1b雾化治疗，对照组加用利巴韦林雾化治疗。结果共有357例纳入统计，治疗组发热、咽痛、咳嗽、喘憋、肺部啰音消失时间及住院时间均优于对照组（ u＝5．83、6．51、6．33、7．39、5．57、6．62，均P＜0．01）；治疗组治愈率及总有效率分别为40．83％、82．92％，明显高于对照组的25．64％、58．12％（χ2＝7．85、25．71，均P＜0．01）；两组均未见明显不良反应。结论重组人干扰素α-1b雾化治疗儿童呼吸道病毒感染性疾病安全有效，方法简单，值得临床推广。
목적：탐토중조인간우소α-1b무화치료인동호흡도병독감염성질병적림상료효급안전성。방법채용수궤、대조적림상시험설계，장375례인동호흡도병독감염성질병환인분위치료조250례화대조조125례，제상규치료외，치료조가용중조인간우소α-1b무화치료，대조조가용리파위림무화치료。결과공유357례납입통계，치료조발열、인통、해수、천별、폐부라음소실시간급주원시간균우우대조조（ u＝5．83、6．51、6．33、7．39、5．57、6．62，균P＜0．01）；치료조치유솔급총유효솔분별위40．83％、82．92％，명현고우대조조적25．64％、58．12％（χ2＝7．85、25．71，균P＜0．01）；량조균미견명현불량반응。결론중조인간우소α-1b무화치료인동호흡도병독감염성질병안전유효，방법간단，치득림상추엄。
Objective To investigate the clinical efficacy and safety of nebulization treatment for childhood respiratory virus infection with human recombinant interferon α-1b.Methods A randomized,controlled clinical re-search was designed.375 subjects with children respiratory tract virus infection were randomly divided into the treat-ment group(250 cases) and control group(125 cases).In addition to conventional therapy,the treatment group with recombinant human interferon α-1b and the control group with ribavirin were executed by using nebulization treat-ment.Results A total of 357 subjects were statistically included in the trail.Sore throat,cough,wheezes,rale of lung disappearing time and the days of hospitalization of treatment group were significantly different(u=5.83,6.51,6.33, 7.39,5.57,6.62,all P<0.01) compared with the control group;The treatment group in the cure rate and total effec-tive rate was significantly higher(χ2 =7.85,25.71,all P<0.01),and no obvious adverse reactions were reported. Conclusion Nebulization treatment of childhood respiratory virus infection with human recombinant interferon α-1b is safe and effective.The method of operation is simple and thus its application is worth promoting in clinic.